Paratek Pharmaceuticals Investor Relations Material

Paratek Pharmaceuticals, Inc. is a biopharmaceutical company that engages in the development and commercialization of antibiotics. The Company is developing Paratek (BDP-LA), a novel antibiotic for the treatment of acute bacterial skin infections and community acquired bacterial pneumonia (CABP) caused by Gram-positive pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA), including those resistant to current therapies. Its product candidates include BDP-LA, SCY-078, PTH analogs that are under development for the treatment of infectious diseases primarily mediated by protein misfolding. In addition to its core expertise in antibiotic research and development activities, it also engages in early stage investments in therapeutic products to create value while reducing risk in the start up process.